Publikationsdatenbank

Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters (2023)

Art

Zeitschriftenartikel / wissenschaftlicher Beitrag

Autoren

Nouailles, Geraldine

Adler, Julia M. (WE 5)

Pennitz, Peter

Peidli, Stefan

Teixeira Alves, Luiz Gustavo

Baumgardt, Morris

Bushe, Judith (WE 12)

Voss, Anne (WE 12)

Langenhagen, Alina (WE 12)

Langner, Christine (WE 5)

Martin Vidal, Ricardo (WE 5)

Pott, Fabian

Kazmierski, Julia

Ebenig, Aileen

Lange, Mona V.

Mühlebach, Michael D.

Goekeri, Cengiz

Simmons, Szandor

Xing, Na (WE 5)

Abdelgawad, Azza (WE 5)

Herwig, Susanne

Cichon, Günter

Niemeyer, Daniela

Drosten, Christian

Goffinet, Christine

Landthaler, Markus

Blüthgen, Nils

Wu, Haibo

Witzenrath, Martin

Gruber, Achim D. (WE 12)

Praktiknjo, Samantha D.

Osterrieder, Nikolaus (WE 5)

Wyler, Emanuel

Kunec, Dusan (WE 5)

Trimpert, Jakob (WE 5)

Quelle

Nature microbiology

Bandzählung: 8

Heftzählung: 5

Seiten: 860 – 874

ISSN: 2058-5276

Sprache

Englisch

Verweise

URL (Volltext): https://www.nature.com/articles/s41564-023-01352-8

DOI: 10.1038/s41564-023-01352-8

Pubmed: 37012419

Kontakt

Institut für Virologie

Robert-von-Ostertag-Str. 7-13
14163 Berlin
+49 30 838 51833
virologie@vetmed.fu-berlin.de

Abstract / Zusammenfassung

Vaccines play a critical role in combating the COVID-19 pandemic. Future control of the pandemic requires improved vaccines with high efficacy against newly emerging SARS-CoV-2 variants and the ability to reduce virus transmission. Here we compare immune responses and preclinical efficacy of the mRNA vaccine BNT162b2, the adenovirus-vectored spike vaccine Ad2-spike and the live-attenuated virus vaccine candidate sCPD9 in Syrian hamsters, using both homogeneous and heterologous vaccination regimens. Comparative vaccine efficacy was assessed by employing readouts from virus titrations to single-cell RNA sequencing. Our results show that sCPD9 vaccination elicited the most robust immunity, including rapid viral clearance, reduced tissue damage, fast differentiation of pre-plasmablasts, strong systemic and mucosal humoral responses, and rapid recall of memory T cells from lung tissue after challenge with heterologous SARS-CoV-2. Overall, our results demonstrate that live-attenuated vaccines offer advantages over currently available COVID-19 vaccines.